* Eledon Pharmaceuticals Inc ELDN.OQ ELDN.O is expected
to show no change in quarterly revenue when it reports
results on November 14.
*
* Refinitiv's mean analyst estimate for Eledon
Pharmaceuticals
Inc is for a loss of 68 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Eledon
Pharmaceuticals Inc is $25, above its last closing price
of $2.53.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 -0.70 -0.70 -0.65 Beat 7.7
Mar. 31 2022 -0.67 -0.68 -0.69 Missed -1.8
Dec. 31 2021 -0.75 -0.59 Beat 21.3
Sep. 30 2021 -0.63 -0.65 -0.66 Missed -2.2
Jun. -0.58 -0.57 -0.50 Beat 11.9
30 2021
Mar. 31 2021 -0.34 -0.32 -0.57 Missed -78.1
Dec. 31 2020 -0.31 -1.39 -2.12 Missed -52
Sep. 30 2020 -1.82 -1.75 -5.51 Missed -215.5
This summary was machine generated November 11 at 23:38 GMT.
All figures in US dollars unless otherwise stated